Moderate to Severe Angina Pectoris Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA™-GUIDED/MYOSTAR™ Catheter in "No Option" Patients With Class II-IV Stable Angina
The primary purpose of this study is to determine whether treatment with an experimental
gene therapy (BIOBYPASS®) will reduce angina in study participants by stimulating the growth
of new blood vessels. This will be measured by testing whether participants are able to
exercise longer without experiencing angina after treatment, as compared to before
treatment.
Additionally, this study will collect information about any side effects that might be
related to the treatment with the experimental therapy.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment